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enning Kelbæk, MD,* Leif Thuesen, MD,† Steffen Helqvist, MD,* Lene Kløvgaard, RN,*
rik Jørgensen, MD,* Samir Aljabbari, MD,* Kari Saunamäki, MD,* Lars R. Krusell, MD,†
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er Thayssen, MD,§ Anders Galløe, MD, Anton van Weert, PHD,¶ for the SCANDSTENT Investigators
openhagen, Skejby, Roskilde, Odense, and Gentofte, Denmark; and Leiden, the Netherlands
OBJECTIVES The purpose of the SCANDSTENT study was to evaluate the use of sirolimus-eluting stents
(SES) in complex coronary lesions.
BACKGROUND The use of SES improves angiographic and clinical outcomes compared with bare-metal
stents (BMS) in simple coronary artery lesions, but there is limited evidence of their safety
and efficacy when implanted in complex lesions.
METHODS We randomly assigned 322 patients with symptomatic complex coronary artery disease to
receive either SES or BMS. The lesions were occluded (36%), bifurcational (34%), ostial
(22%), or angulated (8%) in morphology. The primary end point was the difference in
minimal lumen diameter six months after stent implantation.
RESULTS The patients were well matched in terms of demographic and angiographic baseline
characteristics; 18% had diabetes. The reference vessel diameter was 2.86 mm in mean, and
the lesion length 18.0 mm. At follow-up, patients who received SES had a minimal lumen
diameter of 2.48 mm compared with 1.65 mm in those who received BMS (p  0.001), a
diameter stenosis of 19.3% versus 43.8% (p  0.001), and 2.0% versus 31.9% developed
restenosis (p  0.001). The rate of major adverse cardiac events was 4.3% with SES versus
29.3% with BMS (p  0.001), and stent thrombosis was observed in 0.6% in the SES group
versus 3.1% in the BMS group (p  0.15).
CONCLUSIONS The use of SES markedly reduced restenosis and the occurrence of major adverse cardiac
events in patients with complex coronary artery lesions without increasing the risk of stent
thrombosis. (J Am Coll Cardiol 2006;47:449–55) © 2006 by the American College of
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.10.045Cardiology Foundation
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dompared with balloon angioplasty, stent implantation in
oronary artery lesions improves procedure safety but in-
reases neointimal hyperplasia in the treated vessel, espe-
ially in the presence of diabetes mellitus and complexity of
he treated lesion (1–8). Previous attempts to reduce the
ormation of neointimal hyperplasia with local and systemic
harmaceutical drug therapy have not been successful (9–
1), until recently, when two polymer-based anti-
nflammatory drugs were shown to reduce the rate of
estenosis in simple coronary artery lesions (12–16). Because
atients with complex lesions such as occluded, bifurca-
ional, ostial, and angulated lesions have been excluded from
revious trials, there is uncertainty as to whether implanta-
ion of drug-eluting stents can be performed safely and
fficiently in such complex lesions. We performed the
andomized Stenting Coronary Arteries in Non-Stress/
enestent Disease (SCANDSTENT) trial to evaluate the
linical and angiographic outcome after implantation of
ither sirolimus-eluting stents (SES) or bare-metal stents
BMS) in patients with complex coronary artery lesions.
From *Rigshospitalet, Copenhagen, Denmark; †Skejby Sygehus, Skejby, Denmark;
Roskilde Amtssygehus, Roskilde, Denmark; §Odense Universitets hospital, Odense,
enmark; Gentofte Amtssygehus, Gentofte, Denmark; and ¶Heart Core, Leiden,
he Netherlands. The authors have received unrestricted research grants from Johnson
Johnson.a
Manuscript received September 6, 2005; revised manuscript received September 27,
005, accepted October 11, 2005.ETHODS
atients and study design. The study was a randomized
rial conducted at four cardiology centers in Denmark.
atients were considered eligible if they were older than 18
ears of age, had stable or unstable angina or a recent
on–ST-segment elevation myocardial infarction, and had
ne or more de novo lesions in native coronary vessels
etween 2.25 and 4.50 mm in diameter with one of the
ollowing characteristics: occlusion with a length of 15
m (interrupted contrast filling, Thrombolysis In Myocar-
ial Infarction flow grade 0 or 1), bifurcation (side branch
1.75 mm in diameter to allow balloon dilatation with a
inimum risk of severe dissection), ostial location (5 mm
rom the ostium), or angulations (45° within the lesion).
ajor clinical exclusion criteria were a life expectancy of1
ear, allergy to any of the pharmaceuticals used, and
yocardial infarction less than three days before the proce-
ure. Angiographic exclusion criteria were: 1) lesions lo-
ated in unprotected left main stem coronary arteries and
ypass grafts, and 2) lesions containing visible thrombus.
he protocol was approved by the ethics committee of
openhagen and Frederiksberg, and all patients provided
ritten informed consent.
Patients were pretreated with aspirin (75 mg) and clopi-
ogrel (300 mg), and heparin was administered to maintain
n activated clotting time of 250 s during the procedure.
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Restenosis in Complex Coronary Lesions January 17, 2006:449–55lycoprotein receptor antagonists were used at the discre-
ion of the operator. Cardiac enzymes were measured before
nd 16 to 24 h after the procedure, and 12-lead electrocar-
iograms were obtained before the procedure and before
ischarge from the hospital. Aspirin and clopidogrel were
ontinued indefinitely and for one year after stent implan-
ation, respectively.
Clinical follow-up was performed continuously for seven
onths, and a repeat coronary angiography was scheduled
fter six months. In case recurrent symptoms required a
onscheduled angiogram within three months after stent
mplantation that did not result in revascularization of the
arget lesion, another angiography was performed as sche-
uled. A nonscheduled angiogram performed three to six
onths after stent implantation replaced the six-month
ngiogram.
andomization and stent implantation. Randomization
as performed (1:1) by computerized assignment with
tratification with regard to gender and the presence of
iabetes. The lesions were treated by standard percutaneous
nterventional methods avoiding debulking techniques. The
MS Bx Velocity stent mounted on the balloon expandable
elivery system, Sonic (Cordis/Johnson & Johnson, War-
en, New Jersey) or the SES Bx Velocity stent with
irolimus-eluting properties, Cypher (Cordis/Johnson &
ohnson), were implanted in the lesions under high pressure
12 atm). Implantation of more than one stent was
llowed to cover the entire lesion, and side branch stent
mplantation was performed at the discretion of the opera-
or. Both operator and patient were aware of the assigned
reatment.
uantitative coronary angiography. Coronary angio-
rams were acquired in identical orthogonal projections
fter an intracoronary injection of 0.2 mg of nitroglycerin
efore, immediately after, and six months after stent im-
lantation. All angiograms were analyzed by an indepen-
ent core laboratory whose technicians were blinded both
ith regard to the type of stent implanted and to the clinical
utcome of the patients using the Medis computerized
dge-detection system (Medis, Nuenen, the Netherlands)
17). The reference diameter in ostial lesions and side
ranches of bifurcations was determined immediately dis-
ally to the lesion. Binary restenosis was present whenever
he diameter stenosis was50 %. Late lumen loss (LL) was
etermined as the change in minimal lumen diameter
MLD) from immediately after stent implantation to
Abbreviations and Acronyms
BMS  bare-metal stent
LL  late (lumen) loss
MLD  minimal lumen diameter
SES  sirolimus-eluting stent
TLR  target lesion revascularizationollow-up. Angiographic findings were recorded both inside ahe stent (in-stent) and in the vessel area within 5 mm of its
orders (in-lesion).
tudy end points. The primary end point of the study
as the difference in MLD in the target lesion at
ollow-up as determined by quantitative coronary angiog-
aphy and analyzed by the independent core laboratory,
he main branch being the “target” area of the bifurca-
ional lesions. Secondary end points were LL, the rate of
inary restenosis, percent diameter stenosis at the six-
onth angiography, and the rate of major adverse cardiac
vents occurring within seven months after treatment:
eath, myocardial infarction, or target lesion revascular-
zation (TLR).
A non–Q-wave myocardial infarction during or after the
ntervention was defined as a total creatine kinase elevation
wo times or greater than the upper normal limit with a
oncomitant increase in creatine kinase-myocardial band
lood concentration in the absence of pathologic Q waves.
Q-wave myocardial infarction was defined as the devel-
pment of new Q waves lasting 0.4 s in two or more
ontiguous leads together with clinical signs of a myocardial
nfarction (chest pain or increase in the creatine kinase-
yocardial band).
Target lesion revascularization was defined as repeat
evascularization (percutaneously of the target lesion or
urgical of the vessel containing the target lesion). Revas-
ularization should be performed in the presence of docu-
ented ischemia and a significant stenosis of the lesion.
Stent thrombosis was defined as definite in case of
ngiographically visible signs of a contrast filling defect in
he target lesion in connection with an acute coronary
yndrome. A possible stent thrombosis was present in case
f a sudden and unexpected death during the observation
eriod. Acute, subacute, or late thrombosis occurred within
4 h, within 1 month, or during the succeeding 12 months
fter stent implantation, respectively.
tatistical analysis. With a power of 80% and a two-
ided type 1 error of 0.05, we calculated that 125 patients
n each group would have to complete the study to detect
0.25-mm increase in MLD at follow-up from an
xpected average of 1.64 mm in the BMS group (12) to
.89 mm in the SES group with a standard deviation of
.70 mm. With an expected 15% rate of attrition 150
atients had to be included in each arm of the study.
ith a similar number of patients a reduction in the rate
f major adverse cardiac events from 30% (12) to 18%
ould be detected.
Differences in categorical variables between the two
roups were analyzed using the chi-square test or the Fisher
xact test whenever numbers in a category were 5.
ontinuous variables were analyzed using the Kaplan-Meier
ethod and the log-rank test. All p values were two-sided.
ubgroup analyses were performed by calculating odds
atios for the risk of TLR in patient groups according to age,
ender, and lesion located in the left anterior descending
rtery, in addition to those previously demonstrated to be
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January 17, 2006:449–55 Restenosis in Complex Coronary Lesionsssociated with increased restenosis: presence of diabetes,
ong lesions, and lesions located in small vessels.
Bonferroni adjustment for multiple comparisons was
sed. We calculated cumulative frequency distributions of
he quantitative angiographic measurements before and
fter percutaneous coronary intervention and at follow-
p.
able 1. Baseline Characteristics of Patients and Lesions
Sirolimus-
Eluting
Stent
(n  163)
Bare-Metal
Stent
(n  159) p Value
ge (yrs) 62.9 (9.2) 62.5 (9.4) 0.94
ale gender (%) 74 79 0.30
iabetes (%) 18 18 0.90
ypertension (%) 46 38 0.21
yperlipidemia (%) 81 84 0.46
urrent smoking (%) 36 33 0.82
amily predisposition (%) 45 44 0.91
revious myocardial infarction (%) 54 50 0.58
nstable angina (%) 25 26 0.70
eft ventricular ejection fraction (%) 54 (12) 55 (10) 0.56
revious PCI/CABG (%) 19 16 0.69
ultivessel disease (%) 43 45 0.29
arget lesion coronary artery (%)
LAD 45 53 0.31
LCX 25 23
RCA 30 24
esion length (mm) 18.8 (13.0) 17.2 (11.1) 0.43
esion type (%)
Occlusion, n  115 36 35 0.94
Bifurcation, n  109 35 33
Ostial, n  73 21 24
Angulation, n  25 7 8
umbers are mean values with SD in parentheses.
CABG  coronary artery bypass grafting; LAD  left anterior descending; LCX
left circumflex; PCI  percutaneous coronary intervention; RCA  right coronary
rtery.igure 1. Cumulative frequency of the minimal lumen diameter before (pre), im
n patients who received sirolimus-eluting and bare-metal stents.ESULTS
rocedural and patient characteristics. From October
002 to June 2004, 322 patients were enrolled in the
CANDSTENT trial. The procedural success was 99.4% in
he group receiving SES and 98.7% in the BMS group (p
.91). The data of three patients were precluded from the
nalyses because of technical issues. In two other patients,
he stent could not be inserted into the lesion, and alterna-
ive stents were succesfully used; the data of these two
atients have been analyzed along with the others (accord-
ng to the intention-to-treat principle).
The clinical baseline characteristics of the two patient
roups were well matched, and no differences were found in
aseline angiographic characteristics (Table 1). Seventy-two
atients had a lesion with more than one complexity. We
mplanted 1.4 versus 1.3 stent per patient in the SES versus
he BMS group (p  0.89) with a total stent length of 26.1
m versus 22.6 mm (p  0.60), respectively. Glycoprotein
Ib/IIIa inhibitors were used in 33% of patients in the
irolimus and 31% in the bare-metal stent group (p 0.96).
he reference diameters of side branch bifurcations were
.22 mm and 2.18 mm (p 0.55). Stents were implanted in
5% and 53% of side branches in the two groups (p  0.75)
sing “Y”-, “T”-, and “crush” techniques with similar
requences in the two groups. Side branch treatment after
tent implantation in the main branch was always finalized
ith a “kissing balloons” maneuver.
uantitative coronary angiography analysis. Follow-up
oronary angiography was available in 292 (91%) of the
atients. Figure 1 shows the cumulative frequency curve of
LD before, immediately after, and at six months after
tent implantation. In Table 2, the results of the angio-
raphic analyses are shown, including the main branch of
he bifurcations. The restenosis rate in side branches wasmediately after (post), and six months after (follow-up) stent implantation
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Restenosis in Complex Coronary Lesions January 17, 2006:449–55educed from 42% to 15% (p 0.001). At follow-up, MLD
as significantly larger and the diameter stenosis smaller,
esulting in a 0.04 mm LL in patients who were treated with
ES compared with 0.94 mm in those who received BMS
Table 2). The corresponding rate of in-lesion binary
estenosis was reduced from 32% to 2% (p  0.001).
linical outcomes. The clinical outcomes of the patients are
isted in Table 3. There were no acute stent thromboses within
4 h after stent implantation. There were five cases of definite
angiographically documented) stent thromboses and one case
f possible stent thrombosis. Of the definite stent thromboses,
hree occurred subacutely and two lately. Only one patient
with late stent thrombosis), who developed allergy to clopi-
ogrel and had received ticlopidine for three months, had
iscontinued her antiplatelet therapy three months before
he episode. Stent thrombosis occurred in five patients, with
ifurcational and in one with an ostial lesion. The rate of
yocardial infarction was insignificantly different in the two
roups (Table 3).
able 2. Quantitative Coronary Angiography*
In-Lesion Zone
Sirolimus-Eluting
Stent
(n  62)
Bare-Me
Stent
(n  15
eference vessel diameter (mm) 2.86 (0.53) 2.87 (0.4
inimal lumen diameter (mm)
Before procedure 0.71 (0.67) 0.67 (0.6
After procedure 2.52 (0.51) 2.58 (0.5
At 6-month follow-up 2.48 (0.58) 1.63 (0.8
iameter stenosis (%)
Before procedure 75.9 (22.2) 77.4 (20
After procedure 15.1 (9.0) 14.0 (10
At 6-month follow-up 19.3 (12.8) 43.8 (26
ate lumen loss (mm) 0.04 (0.50) 0.94 (0.7
inary (50%) restenosis (%) 3 (2.0) 46 (31
umbers are mean values with SD in parentheses. *Only main branches of bifurcati
Table 3. Major Adverse Cardiac Events Durin
Si
Death
Myocardial infarction
STEMI
NSTEMI
Target lesion revascularization in subgroups
Occlusions, n  115
Bifurcations, n  109
Ostial lesions, n  73
Angulations, n  25
Total
Any MACE
Stent thrombosis
One sudden death (possible stent thrombosis).
MACE  major adverse cardiac event; NSTEMI  non–
ST-segment elevation myocardial infarction.The rate of TLR was lower in the SES group (Table 3).
aplan-Meier estimates of event-free survival are shown in
igure 2. The results of the subgroup analyses are illustrated
n Figure 3, demonstrating a significant difference favoring
ES in all subsets of patients also in those previously found
o be associated with an increased risk of restenosis after
mplantation of BMS.
ISCUSSION
e tested the hypothesis that SES would be superior to the
orresponding BMS with regard to the angiographic out-
ome in complex coronary artery lesions. The main result of
he SCANDSTENT study was a marked reduction of
eointimal hyperplasia in patients who had one or more
ES implanted. Despite the complex nature of all the
esions included in the study, the MLD at follow-up in the
are-metal stent group was of the same magnitude as in
revious trials of less complex lesions. Our study was
owered to detect a difference in MLD of at least 0.25 mm
In-Stent Zone
p Value
Sirolimus-Eluting
Stent
(n  162)
Bare-Metal
Stent
(n  157) p Value
0.49 2.86 (0.53) 2.87 (0.48) 0.49
0.71 0.71 (0.67) 0.67 (0.62) 0.71
0.27 2.60 (0.48) 2.66 (0.53) 0.21
0.001 2.58 (0.59) 1.65 (0.82) 0.001
0.53 75.9 (22.2) 77.4 (20.1) 0.53
0.19 12.8 (7.4) 11.6 (8.3) 0.08
0.001 16.4 (11.4) 43.1 (26.3) 0.001
0.001 0.02 (0.42) 1.01 (0.75) 0.001
0.001 3 (2.0) 44 (30.6) 0.001
en Months of Follow-Up
% of Patients
us-Eluting
tent
 162)
Bare-Metal
Stent
(n  157) p Value
0.6 0.6 1.0
0.28
0.6 1.2
0.6 1.9
0 32.1
7.1 29.4
0 35.1
0 0
2.5 29.3 0.001
4.3 29.9 0.001
0.6 3.1 0.12tal
7)
8)
2)
6)
2)
.1)
.1)
.1)
4)
.9)g Sev
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January 17, 2006:449–55 Restenosis in Complex Coronary Lesionsetween the two groups, a difference that was markedly
xceeded.
omparison with other studies. Our results demonstrated
90% relative reduction in the rate of restenosis in patients
ho had SES implanted in comparison with the corre-
ponding stent without drug-eluting properties. This mark-
dly reduced restenosis rate was of the same magnitude as
hat found in other drug-eluting stent studies despite a
igher level of lesion complexity in our patients. Whereas
he frequency of TLR of less complex lesion types are
sually lower than the angiographic restenosis rate
13,14,16), most of our patients with angiographic resteno-
is were treated with a repeat angioplasty because of recur-
ence of symptoms. This discrepancy may reflect a more
ronounced clinical importance of the development of
estenosis in a complex than in a simple coronary lesion.
The mean pretreatment diameter stenosis of the lesions
n the present study was considerably higher than in other
tudies, which is explained by a relatively large fraction of
atients with total and subtotal occlusions. Randomized
tudies of the treatment of total coronary occlusions have
emonstrated a reduction in the restenosis rate from ap-
roximately 70% in the balloon-treated groups compared
ith a variety of 30% to 55% in the stent groups dependent
n lesion complexity, with a corresponding reduction in the
eed for revascularization and with no increased risk of stent
hrombosis (18–20).
No randomized studies have been published comparing
rug-eluting and BMS implantation in lesions located in
ifurcations. A small randomized comparison of stenting or
ot stenting the side branch with SES showed improved
esults compared with historical BMS controls with regard
o the rate of restenosis but did not give a solution to the
Figure 2. Kaplan-Meier estimates of event-free survival amoroblem (21). BPatients with lesions located in bifurcations were in-
luded in the SCANDSTENT study provided the side
ranch had a diameter that allowed stent implantation in
ost cases. With the only restriction that all vessels should
referably stay open after the procedure, the side branches
ere treated at the discretion of the operator. We found
onsiderably better angiographic results after implantation
f SES compared with BMS in the main branches of the
ifurcations, and although the operators chose to implant
tents in only slightly more than half of the side branches in
oth groups, the angiographic results of the side branches
lone were considerably better in the SES group. Accord-
ngly, the rates of TLR of the side branches were signifi-
antly higher in the BMS group.
That stent implantation gives better results compared
ith balloon angioplasty in ostial lesions of the left anterior
escending artery have been reported previously (22). In
ddition, the implantation of SES in ostial lesions seems to
mprove both clinical and angiographic outcome compared
ith treatment with conventional BMS (23). Both ostial
nd tortuous lesions have been excluded from previous
andomized drug-eluting stent trials. The SCANDSTENT
tudy demonstrates significantly better results with SES
ompared with BMS in these complex lesions.
redictors of restenosis. Some other important predictors
f restenosis, the presence of diabetes mellitus and the
ength of the treated lesions, have to be considered
5,7,14,24). Compared with other studies, our patient pop-
lation had a slightly lower frequency of diabetic patients in
oth groups, whereas our patients had considerably longer
esions than those treated in previous trials. Subgroup
nalyses of our patients showed a consistent benefit of SES
n TLR. That the risk factors of developing restenosis after
tients who received sirolimus-eluting and bare-metal stents.MS implantation turned out to be of limited value in
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Restenosis in Complex Coronary Lesions January 17, 2006:449–55atients treated with SES calls for a revision of these risk
actors in the new stent era. Among lesion types, all except
ngulated lesions had a similar benefit of SES stenting.
tent thrombosis. The rate of stent thrombosis in the
resent study was of the same magnitude as those reported
n previous trials of BMS treatment of less complex lesions
13–16). In two meta-analyses, the rate of stent thrombosis
fter drug-eluting stent implantation was 1% (25,26) and,
n a large registry, the rate was 2.6% after implantation of
MS and 1% after drug-eluting stents (27). Accordingly,
ost of the stent thromboses occurring in our study were
bserved in the BMS group. A low rate of stent thombosis
n our SES patients could be caused by selection bias.
owever, Jeremias et al. (28) found a 1% rate of stent
hrombosis in a consecutive series of SES implantations that
nvolved 20% of bifurcations. Diabetes was present in 37%
f their patients, whereas the frequency of diabetes in our
tudy was lower. The results of the present study revealed
hat SES can be used in a high fraction of “everyday
atients” without further risk of adverse events. Because all
efinite cases of stent thrombosis occurred in patients who
ad BMS implanted in bifurcation lesions, we recommend
hat implantation of BMS in such lesions is carefully
igure 3. Subgroup analysis for the six-month rate of target lesion revasc
escending; RCA  right coronary artery.onsidered. otudy limitations. A methodological limitation of the
resent study was the open design of the treatment,
mplicating that both operators and patients were aware
f the nature of the implanted stents. Accordingly, a
ertain bias in both patients’ and physicians’ interpreta-
ion of symptoms at follow-up might be expected. How-
ver, it is highly unlikely that this knowledge of stent
ypes should have had any impact on the development of
ngiographic changes, which were analyzed blindly. Fur-
hermore, all clinical end points were adjudicated by a
linded clinical events committee, that found only two
ases in which the operator, contrary to the core labora-
ory, judged the lesion severity as to necessitate revascu-
arization. Although the results of the SCANDSTENT
tudy broaden the indication for implantation of drug-
luting stents, only long-term follow-up of the patients
ill ensure the durability of these initially promising
esults (29 –31).
onclusions. In conclusion, implantation of SES results in
mproved angiographic and clinical results compared with
MS in certain complex coronary artery lesions. The
uperior results are not associated with any increase in the
ation. CI  confidence interval; CX  circumflex; LAD  left anteriorccurrence of stent thrombosis.
R
C
C
R
1
1
1
1
1
1
1
1
1
1
2
2
2
2
2
2
2
2
2
2
3
3
455JACC Vol. 47, No. 2, 2006 Kelbæk et al.
January 17, 2006:449–55 Restenosis in Complex Coronary Lesionseprint requests and correspondence: Dr. Henning Kelbæk,
ardiac Catheterization Laboratory 2013, Rigshospitalet, DK–2100,
openhagen, Denmark. E-mail: henning.kelbaek@rh.hosp.dk.
EFERENCES
1. Sigwart U, Puel J, Mirkowitch V, Joffre F, Kappenberger L. Intravas-
cular stents to prevent occlusion and restenosis after transluminal
angioplasty. N Engl J Med 1987;316:701–6.
2. Roubin GS, Cannon AD, Agrawal SK, et al. Intracoronary stenting
for acute and threatened closure complicating percutaneous translu-
minal coronary angioplasty. Circulation 1992;85:916–27.
3. Fischman DL, Leon MB, Baim DS, et al. A randomized comparison
of coronary-stent placement and balloon angioplasty in the treatment
of coronary artery disease. N Engl J Med 1994;331:496–501.
4. Serruys PW, van Hout B, Bonnier H, et al. Randomised comparison
of implantation of heparin-coated stents with balloon angioplasty in
selected patients with coronary artery disease. Lancet 1998;352:
673–81.
5. Kastrati A, Schömig A, Elezi S, et al. Predictive factors of restenosis
after coronary stent placement. J Am Coll Cardiol 1997;30:
1428–36.
6. Hoffmann R, Mintz GS, Dussaillant GR, et al. Patterns and mecha-
nisms of in-stent restenosis: a serial intravascular ultrasound study.
Circulation 1996;94:1247–54.
7. Jørgensen E, Kelbæk H, Helqvist S, et al. Predictors of coronary
in-stent restenosis: importance of angiotensin-converting enzyme gene
polymorphism and treatment with angiotensin-converting enzyme
inhibitors. J Am Coll Cardiol 2001;38:1434–9.
8. Colombo A, Hall P, Nakamura S, et al. Intracoronary stenting without
anticoagulation accomplished with intravascular ultrasound guidance.
Circulation 1995;91:1676–88.
9. de Feyter P, Vos J, Rensing BJ. Anti-restenosis trials. Curr Interv
Cardiol Rep 2000;2:326–31.
0. Holmes DR, Savage M, LaBlanche JM, et al. Results of Prevention of
Restenosis with Tranilast and its Outcomes (PRESTO) trial. Circu-
lation 2002;106:1243–50.
1. Hoffmann R, Mintz GS. Coronary in-stent restenosis—predictors,
treatment and prevention. Eur Heart J 2000;21:1739–49.
2. Morice M-C, Serruys PW, Sousa JE, et al. A randomized comparison
of a sirolimus-eluting stent wth a standard stent for coronary revascu-
larization. N Engl J Med 2002;346:1773–80.
3. Schofer J, Schlüter M, Gershlick AH, et al. Sirolimus-eluting stents
for treatment of patients with long atherosclerotic lesions in small
coronary arteries: double-blind randomised controlled trial (E-SIRIUS).
Lancet 2003;362:1093–9.
4. Moses JW, Leon MB, Popma JJ, et al. Sirolimus-eluting stents versus
standard stents in patients with stenosis in a native coronary artery.
N Engl J Med 2003;349:1315–23.5. Colombo A, Drzewiecki J, Banning A, et al. Randomized study to
assess the effectiveness of slow- and moderate-release polymer-basedpaclitaxel-eluting stent for coronary artery lesions. Circulation
2003;108:788–94.
6. Stone GW, Ellis SG, Cox DA, et al. A polymer-based, paclitaxel-
eluting stent in patients with coronary artery disease. N Engl J Med
2004;350:221–31.
7. van Weert A, Lesperance J, Reiber JHC. Standardization of central
off-line quantitative image analysis: implications from experiences with
quantitative coronary angiography. Heart Drug 2001;1:44–51.
8. Buller CE, Dzavik V, Carere RG, et al. Primary stenting versus
balloon angioplasty in occluded coronary arteries: the Total Occlusion
Study of Canada (TOSCA). Circulation 1999;100:236–42.
9. Sirnes PA, Golf S, Myreng Y, et al. Stenting In Chronic Coronary
Occlusion (SICCO): a randomised controlled trial of adding stent
implantation after successful angioplasty. J Am Coll Cardiol 1996;28:
1444–51.
0. Rubartelli P, Verna E, Nicolli L, et al. Coronary stent implantation is
superior to balloon angioplasty for total coronary occlusions. J Am Coll
Cardiol 2003;41:1488–92.
1. Colombo A, Moses J, Morice MC, et al. Randomized study to
evaluate sirolimus-eluting stents implanted at coronary bifurcation
lesions. Circulation 2004;109:1244–9.
2. Versaci F, Gaspardone A, Tomai F, et al. A comparison of coronary-
artery stenting with angioplasty for isolated stenosis of the proximal
left anterior descending coronary artery. N Engl J Med 1997;336:
817–22.
3. Iakovou I, Ge L, Michev I, et al. Clinical and angiographic outcome
after sirolimus-eluting stent implantation in aorto-ostial lesions. J Am
Coll Cardiol 2004;44:967–71.
4. Mercado N, Boersma E, Wijns W, et al. Clinical and quantitative coronary
angiographic predictors of coronary restenosis: a comparative analysis from the
balloon-to-stent era. J Am Coll Cardiol 2001;38:645–52.
5. Bavry AA, Kumbhani DJ, Helton TJ, Bhatt DL. What is the risk of stent
thrombosis associated with the use of paclitaxel-eluting stents for percu-
taneous coronary intervention? J Am Coll Cardiol 2005;45:941–6.
6. Moreno R, Fernandez C, Hernandez R, et al. Drug-eluting stent
thrombosis. Results from a pooled analysis including 10 randomized
studies. J Am Coll Cardiol 2005;45:954–9.
7. Ong ATL, Hoye A, Aoki J, et al. Thirty-day incidence and six-month
clinical outcome of thrombotic stent occlusion after bare-metal,
sirolimus, or paclitaxel stent implantation. J Am Coll Cardiol 2005;
45:947–53.
8. Jeremias A, Sylvia B, Bridges J, et al. Stent thrombosis after successful
sirolimus-eluting stent implantation. Circulation 2004;109:1930–2.
9. Vermani R, Liistro F, Stankovic G, et al. Mechanism of late in-stent
restenosis after implantation of a paclitaxel derivate-eluting polymer
stent system in humans. Circulation 2002;106:2649–51.
0. Degertekin M, Serruys PW, Tanabe K, et al. Long-term follow-up of
incomplete stent apposition in patients who received sirolimus-eluting
stents for de novo coronary lesions: an intravascular ultrasound
analysis. Circulation 2003;108:2747–50.
1. Tanabe K, Serruys PW, Degertekin M, et al. Chronic arterial
responses to polymer-controlled paclitaxel-eluting stents. Circulation
2004;109:196–200.
